Drugs in ATC Class D10AA

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D10 - ANTI-ACNE PREPARATIONS

Up to D10A - ANTI-ACNE PREPARATIONS FOR TOPICAL USE

Drugs in ATC Class: D10AA - Corticosteroids, combinations for treatment of acne

Tradename	Generic Name
FLUOR-OP	fluorometholone
FLUOROMETHOLONE	fluorometholone
FML	fluorometholone
OXYLONE	fluorometholone

D10AA Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class D10AA (Corticosteroids, combinations for treatment of acne) reflect a growing emphasis on advanced combination therapies within the broader acne treatment sector. Below is a detailed analysis:

---

Market Dynamics

Growth Drivers

• Rising Prevalence of Skin Conditions: Skin disorders like acne affect over 64.5% of surveyed populations in Europe, with 11.7% suffering from eczema and 25.5% from rosacea, driving demand for corticosteroid-based treatments[5][10].
• Segmented Market Growth: While the global acne therapeutics market is projected to reach USD 11.51 billion by 2030 (CAGR: 4.89%)[13], the topical corticosteroids market specifically is growing at 6.1% CAGR, expected to hit $6.42 billion by 2030[5]. D10AA products are part of this expansion, particularly for managing inflammatory acne.
• Technological Advancements: Innovations in drug delivery systems, such as Sol-Gel’s stabilization technology in Twyneo (tretinoin + benzoyl peroxide), highlight the trend toward stable combination therapies[3][14]. Though Twyneo isn’t a corticosteroid product, its success underscores the market’s appetite for multi-mechanistic treatments.

Key Challenges

• Side Effects: Topical corticosteroids like dexamethasone can cause skin irritation, erythema, and dermatitis[3][10], necessitating careful formulation to balance efficacy and tolerability.
• Competition from Alternatives: Oral antiandrogens (e.g., spironolactone) and retinoids dominate acne treatment, with spironolactone showing 50–100% improvement rates in trials[8].

Regional Trends

• North America leads due to high R&D investment, FDA approvals (e.g., Twyneo in 2021[3]), and advanced healthcare infrastructure[5][7].

---

Patent Landscape

Key Patents and Innovations

1. Twyneo (tretinoin + benzoyl peroxide):
   • FDA-approved in 2021 with patent protection until 2038[3]. While not a corticosteroid combination, its success validates combination therapy strategies relevant to D10AA.
2. Fluorometholone Combinations:
   • Patent US11045479 (2021) covers treatments for resistant acne, including fluorometholone-based formulations[15]. This aligns with D10AA’s scope (e.g., D10AA03: dexamethasone)[12].
3. XYNGARI™ (Dermata Therapeutics):
   • A 2025 patent (US12,208,123) protects Spongilla-based technology for acne treatment, reflecting continued innovation in topical therapies, though not corticosteroid-specific[4].

Competitive Positioning

• Dexamethasone: A cornerstone of D10AA, it has 15 U.S. patents and 71 global patents, with 39 suppliers listed[6]. Despite generic competition, novel combinations could extend patent viability.
• Pipeline Developments: Companies like Bausch Health and Galderma focus on combination therapies (e.g., triple-combination gel Cabtreo), signaling potential crossover into corticosteroid combinations[14].

---

Future Outlook

• Regulatory Opportunities: Expedited approvals for acne therapies (e.g., Twyneo’s 2021 FDA clearance) may encourage D10AA innovations[3].
• Strategic R&D: Addressing corticosteroid side effects through improved delivery systems (e.g., slow-release formulations) could unlock growth.
• Market Expansion: Asia-Pacific regions, with rising healthcare spending and acne prevalence, offer untapped potential[7][11].

---

Key Takeaways

• The D10AA market benefits from broader acne treatment trends but faces competition from non-corticosteroid therapies.
• Patent activity focuses on stabilizing combination therapies and addressing antibiotic resistance[15].
• Strategic partnerships and technological advancements will drive future growth, particularly in North America and Asia-Pacific.

---

“The FDA approval of Twyneo underscores our ability to deliver innovative, proprietary drugs to the market.” – Dr. Alon Seri-Levy, CEO of Sol-Gel[3].

Cited Sources: [3][5][6][10][12][14][15]

References

1. https://patents.google.com/patent/AU2018375738A1/en
2. https://www.marketsandmarkets.com/Market-Reports/air-traffic-control-equipment-market-159216929.html
3. https://www.uspharmacist.com/article/fda-approves-first-fixeddose-combination-topical-medication-for-acne-vulgaris
4. https://www.biospace.com/press-releases/dermata-expands-patent-portfolio-with-issuance-of-new-u-s-patent-for-next-generation-acne-treatment
5. https://www.databridgemarketresearch.com/reports/global-topical-corticosteroids-market
6. https://www.drugpatentwatch.com/p/generic/dexamethasone
7. https://www.expertmarketresearch.com/reports/air-traffic-control-atc-market
8. https://en.wikipedia.org/wiki/Spironolactone
9. https://en.wikipedia.org/wiki/ATC_code_D10
10. https://www.danishskincare.com/blogs/guides/steroid-acne-management-strategies
11. https://www.alliedmarketresearch.com/air-traffic-control-equipment-market
12. https://atcddd.fhi.no/atc_ddd_index/?code=D10AA&showdescription=yes
13. https://www.mordorintelligence.com/industry-reports/acne-therapeutics-market
14. https://www.grandviewresearch.com/industry-analysis/acne-drugs-market
15. https://patents.justia.com/patent/11045479